id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-D-4490-0002,FDA,FDA-2024-D-4490,Combined FDA and Sponsor Oncologic Drugs Advisory Committee Briefing Document; Guidance for Industry - Draft Guidance,Other,Guidance,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2025-03-01T02:00:35Z,,1,0,09000064868954be
FDA-2024-D-4490-0001,FDA,FDA-2024-D-4490,"Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing
Document; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,,2024-12-30T14:15:28Z,2024-31305,0,0,09000064868952fc